When was Garuda founded?

Garuda was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Garuda located?

Garuda is headquartered in Natick, United States. It is registered at 22 Strathmore Road Natick, MA 01760 USA.

How many employees does Garuda have?

As of Sep 30, 2026, the latest employee count at Garuda is 9.

Is Garuda a funded company?

Garuda is a funded company, having raised a total of $182M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 23, 2021.

When was the latest funding round of Garuda?

Garuda's latest funding was a $***** Series B round on Oct 17, 2024, with participation from 0 investor.

Where does Garuda rank among its competitors?

Garuda ranks 134th amongst 490 active competitors, of which 152 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of Garuda?

Garuda's top competitors include BeiGene, Biogen and argenx. Among them, DBV Technologies secured the most recent funding round in April, 2025.

Garuda - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of stem cell-based therapies to treat multiple diseases. The company has developed stem cell transplants by using targeted antibodies and increasing stem cell numbers by targeting self-renewal pathways. The company's pipeline includes therapeutic indications in hematologic malignancies, sickle cell disease, β-thalassemia, bone marrow failure diseases, and more.

Website: garudatx.com
Email ID: *****@garudatx.com
Registered Address: 22 Strathmore Road Natick, MA 01760 USA

Key Metrics

Founded Year

2021

Location

Natick, United States

Stage

Series B

Total Funding

$182M in 3 rounds

Latest Funding Round

Series B, Oct 17, 2024, $*****

Investors

Orbimed & 10 more

Ranked

134^th among 490 active competitors

Employee Count

9 as on Sep 30, 2026

Similar Companies

BeiGene & 567 more

View Garuda's full profile

Garuda is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
GARUDA THERAPEUTICS, INC CIN: 86-3018867 , United States, Active	Mar 28, 2021	-	53 (As on Dec 31, 2023)	-

Garuda has raised a total funding of $182M over 3 rounds. Its first funding round was on Sep 23, 2021. Garuda has 11 institutional investors.

Here is the list of recent funding rounds of Garuda:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 17, 2024	9984868	Series B	8528757	6847897	9518238	4051758
Feb 09, 2023	4362160	Series B	2699259	7062562	9890595	Sectoral & 2 more
Sep 23, 2021	5791149	Series A	8040779	3332848	Aisling Capital & 2 more	Ridgeback Capital Management & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Garuda's funding rounds and investors

The founders of Garuda are Sean Morrison and David Scadden. Laurie Vallas is the CEO of Garuda.

Here are the details of Garuda's key team members:

Sean Morrison: Co-Founder of Garuda.
David Scadden: Co-Founder of Garuda.

View details of Garuda's Founder profiles and Board Members

Garuda's employee count trend

Garuda has 9 employees as of Sep 26. Here is Garuda's employee count trend over the years:

Uncover Garuda's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Garuda include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Garuda, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
4th	CareDx 1998, Brisbane (United States), Public	Developer of medical solutions for transplant patients	$138M	Intel, Integral Capital Partners & 25 others	73/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
7th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	69/100
8th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	68/100
10th	Theravance Biopharma 2001, Francisco (United States), Public	Developer of therapeutics for inflammatory and immunological diseases	-	Sierra Ventures, Acorn Bioventures & 6 others	68/100
134th	Garuda 2021, Natick (United States), Series B	Developer of stem cell-based therapies to treat multiple diseases	$182M	Sectoral, Aisling Capital & 9 others	45/100